Boots Anaesthetic Sore Throat Relief 2% w/v Spray

Summary of Product Characteristics Updated 21-Dec-2023 | THE BOOTS COMPANY PLC

1. Name of the medicinal product

Anaesthetic Throat Spray

Boots Anaesthetic Sore Throat Relief 2 % w/v Spray

2. Qualitative and quantitative composition

Active ingredient


Lidocaine hydrochloride monohydrate

(Lignocaine hydrochloride monohydrate)


Excipients of known effect


Sorbitol solution 70% (non-crystalising)

15 w/v

Sodium Citrate

0.035 w/v

Alcohol 96%

30 % v/v

For a full list of excipients, see section 6.1

3. Pharmaceutical form

Oromucosal spray

4. Clinical particulars
4.1 Therapeutic indications

For the symptomatic relief of severe sore throats.

4.2 Posology and method of administration

Adults and children over 12 years: Three sprays.

Aim nozzle at back of throat and spray on to the affected area. Repeat the dose every three hours as needed up to a maximum of six times in 24 hours.

Children under 12 years: Should not be given to children less than 12 years of age.

Elderly: There is no need for dose reduction in the elderly.

4.3 Contraindications

Hypersensitivity to any of the ingredients. Patients suffering from asthma or bronchospasm. Children under 12 years.

4.4 Special warnings and precautions for use

Do not use if you are sensitive to any of the ingredients.

Avoid contact with the eyes.

Children under 12 years of age should not be given this medicine.

Do not inhale whilst using the spray.

Do not exceed the stated dose.

Keep all medicines out of the reach of children.

Seek medical advice if symptoms persist or are accompanied by high fever, headache, nausea or vomiting.

Seek medical advice before using this product if you are pregnant, breastfeeding or receiving any medical treatment.

This product may cause numbness of the tongue and therefore care should be taken in eating and drinking hot foods.

Information about some of the ingredients:

This medicine contains 60 mg sorbitol in each 0.40 g dose.

This medicine contains less than 1 mmol sodium (23 mg) per 0.40 g dose, that is to say essentially 'sodium-free'.

This medicine contains 120 mg of alcohol (ethanol) in each 0.40 g dose. The amount in each 0.40 g dose of this medicine is equivalent to less than 6.0 ml beer or 2.4 ml wine.

The small amount of alcohol in this medicine will not have any noticeable effects.

4.5 Interaction with other medicinal products and other forms of interaction

No clinically significant interactions are known.

4.6 Pregnancy and lactation

The safety of this medicinal product for use in human pregnancy has not been established. Experimental animal studies are insufficient to assess the safety with respect to the development of the embryo or foetus, the course of gestation and peri- and post-natal development. The product is, therefore, not recommended during pregnancy and lactation except under medical supervision.

4.7 Effects on ability to drive and use machines

No adverse effects are known.

4.8 Undesirable effects

Occasional hypersensitivity reactions.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Symptoms of overdose include yawning, restlessness, excitement, nervousness, dizziness, nystagmus, tinnitus, blurred vision, nausea, vomiting, muscle twitching, tremors and convulsions. Excitation may be transient and followed by depression with drowsiness, respiratory failure and coma. There may be simultaneous effects on the cardiovascular system with myocardial depression and peripheral vasodilatation, resulting in hypotension, arrhythmias and cardiac arrest.

Very rarely, methaemoglobinaemia may occur with excessive exposure to some local anaesthetics. This is much more commonly seen with benzocaine and prilocaine than with lidocaine. Risk is increased in patients with hereditary methaemoglobinaemia and when used with other oxidising agents.

Treatment consists essentially of maintaining the circulation and respiration and controlling convulsions. The circulation may be maintained with infusions of plasma or suitable electrolyte solutions. Convulsions may be controlled by the intravenous administration of diazepam. If necessary, suxamethonium together with endotracheal intubation and artificial respiration may be used if convulsions persist. Methaemoglobinaemia may be treated by intravenous administration of 1-4 mg/kg methylene blue injection.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Lidocaine is a local anaesthetic of the amide type.

5.2 Pharmacokinetic properties

Lidocaine is readily absorbed from mucous membranes. The plasma elimination half-life is about two hours.

Lidocaine undergoes significant first pass metabolism in the liver and is rapidly de-ethylated to the active metabolite monoethylglycinexylidide and then hydrolysed to various metabolites including glycinexylidide. Less than 10% is excreted unchanged by the kidneys. The metabolites are also excreted in the urine.

5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included.

6. Pharmaceutical particulars
6.1 List of excipients

Sorbitol solution 70% (non-crystallising)


Peppermint Flavour

Aniseed Flavour

Sodium Citrate


Alcohol 96%

Patent Blue V E131

Quinoline Yellow E104

Water Purified

6.2 Incompatibilities

None stated.

6.3 Shelf life

36 months.

6.4 Special precautions for storage


6.5 Nature and contents of container

A clear glass bottle fitted with metering valve spray pump with an extended polypropylene nozzle.

Pack size: 20, 30 millilitres.

6.6 Special precautions for disposal and other handling

On first use or after prolonged storage, spray 3 times away from the face into a sink.

Swing nozzle through 90° and spray on the back of the throat.

7. Marketing authorisation holder

The Boots Company PLC

1 Thane Road West

Nottingham NG2 3AA

Trading as: Boots Pharmacy

Trading as: BCM

8. Marketing authorisation number(s)

PL 00014/0430

9. Date of first authorisation/renewal of the authorisation

Date of First Authorisation:


Date of Last Renewal:


10. Date of revision of the text

01 Dec 2023

Company Contact Details

1 Thane Road West, Beeston, Nottingham, NG2 3AA


+44 (0)1159 592 565


+44 (0)1159 595 165